A Phase 3 interventional study of Adalimumab and Placebo in Ulcerative Colitis, sponsored by AbbVie. Completed at 60 sites in 14 countries. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-10-05.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.
Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 12th largest by enrollment, is one of 2 that started in 2014, is one of 10 in phase 3, and was the 10th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 4 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 152 across the 18 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
53 studies in Colitis, Ulcerative by AbbVie: 6 open now, 13 under way, 5 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2014, is one of 19 in phase 3, and was the 15th registered.
AbbVie’s Colitis, Ulcerative studies by the year they started, since 2000.
1 of the studies testing adalimumab in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06257875AbbVieA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing adalimumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and matching placebo at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
Biological: Adalimumab · Biological: Placebo
Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
Biological: Adalimumab
(After Amendment 4) participants assigned to open-label adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
Biological: Adalimumab
(Prior to Amendment 4) participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to maintenance placebo. Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after the second flare.
Biological: Adalimumab · Biological: Placebo
Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance standard dose (0.6 mg/kg \[maximum dose of 40 mg\] every other week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
Biological: Adalimumab
Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance high dose (0.6 mg/kg \[maximum dose of 40 mg\] every week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
Biological: Adalimumab
Subcutaneous (SC) injection
Also known as: Humira
Subcutaneous (SC) injection
Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 sub scores (stool frequency, rectal bleeding and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in PMS indicates improvement. Clinical remission was defined as a PMS ≤ 2 and no individual subscore \> 1.
Time frame: Week 8
Co-Primary Endpoint 2: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52 in Week 8 Responders Per PMS - Maintenance Period
The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
Time frame: Week 52
Ranked Secondary Endpoint 1: Percentage of Participants With Clinical Response Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period
The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical response per FMS is defined as a decrease in FMS ≥ 3 points and ≥ 30% from Baseline.
Time frame: Week 52
Ranked Secondary Endpoint 2: Percentage of Participants With Mucosal Healing at Week 52 in Week 8 Responders Per PMS - Maintenance Period
The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those participants with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Mucosal healing per Mayo endoscopy subscore is defined as a subscore of ≤ 1.
Time frame: Week 52
Ranked Secondary Endpoint 3: Percentage of Participants With Clinical Remission Per FMS at Week 52 in Week 8 Remitters Per PMS - Maintenance Period
The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS remitters are defined as those participants with a PMS ≤ 2 and no individual subscore \> 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
Time frame: Week 52
Ranked Secondary Endpoint 4: Percentage of Participants With Corticosteroid-Free Clinical Remission Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period
The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from baseline. Among participants receiving systemic corticosteroids at Baseline, corticosteroid-free clinical remission per FMS at Week 52 is defined as having discontinued systemic corticosteroids prior to Week 52 and being in FMS clinical remission at Week 52 (defined as Mayo Score ≤ 2 and no individual subscore \> 1).
Time frame: Week 52
Prior to Protocol Amendment 4, participants were randomized 3:2 at baseline to adalimumab induction high dose or adalimumab induction standard dose. At Week 8, those demonstrating a clinical response per Partial Mayo Score (PMS) were randomized 2:2:1 to adalimumab maintenance standard dose, adalimumab maintenance high dose, or maintenance placebo.
| Milestone | Integrated Study: Induction Standard Dose (I-SD) | Integrated Study: Induction High Dose (I-HD) | Integrated Study: Induction High Dose Open Label (I-HD-OL) | Integrated Study: Maintenance Placebo (M-PL) | Integrated Study: Maintenance Standard Dose (M-SD) | Integrated Study: Maintenance High Dose (M-HD) |
|---|---|---|---|---|---|---|
| Started | 32 | 51 | 18 | 0 | 0 | 0 |
| Enrolled in main study | 30 | 47 | 16 | 0 | 0 | 0 |
| Enrolled in japan sub-study | 2 | 4 | 2 | 0 | 0 | 0 |
| Completed | 22 | 43 | 16 | 0 | 0 | 0 |
| Not completed | 10 | 8 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Requires alternative/prohibited therapy | 1 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Non-responder at week 8 | 4 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Integrated Study: Induction Standard Dose (I-SD) | Integrated Study: Induction High Dose (I-HD) | Integrated Study: Induction High Dose Open Label (I-HD-OL) | Integrated Study: Maintenance Placebo (M-PL) | Integrated Study: Maintenance Standard Dose (M-SD) | Integrated Study: Maintenance High Dose (M-HD) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 12 | 33 | 36 |
| Completed | 0 | 0 | 0 | 11 | 25 | 32 |
| Not completed | 0 | 0 | 0 | 1 | 8 | 4 |
| Withdrew: Requires alternative/prohibited therapy | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 5 | 2 |
| Withdrew: Subject non-compliance | 0 | 0 | 0 | 0 | 0 | 1 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 sub scores (stool frequency, rectal bleeding and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in PMS indicates improvement. Clinical remission was defined as a PMS ≤ 2 and no individual subscore \> 1.
| percentage of participants | Main Study: I-SD | Main Study: I-HD | Main Study: I-SD + I-HD | Main Study: I-HD-OL | Integrated Study (Main + Japan Sub-Study): I-SD | Integrated Study (Main + Japan Sub-Study): I-HD | Integrated Study (Main + Japan Sub-Study): I-SD + I-HD | Integrated Study (Main + Japan Sub-Study): I-HD-OL |
|---|---|---|---|---|---|---|---|---|
| Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period | 43.3 (25.46 to 62.57) | 59.6 (44.27 to 73.63) | 53.2 (41.52 to 64.71) | 68.8 (41.34 to 88.98) | 40.6 (23.70 to 59.36) | 58.8 (44.17 to 72.42) | 51.8 (40.56 to 62.92) | 66.7 (40.99 to 86.66) |
The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
| percentage of participants | Main Study: M-PL | Main Study: M-SD | Main Study: M-HD | Main Study: M-SD + M-HD | Integrated Study (Main + Japan Sub-Study): M-PL | Integrated Study (Main + Japan Sub-Study): M-SD | Integrated Study (Main + Japan Sub-Study): M-HD | Integrated Study (Main + Japan Sub-Study): M-SD + M-HD |
|---|---|---|---|---|---|---|---|---|
| Co-Primary Endpoint 2: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52 in Week 8 Responders Per PMS - Maintenance Period | 33.3 (9.92 to 65.11) | 29.0 (14.22 to 48.04) | 45.2 (27.32 to 63.97) | 37.1 (25.16 to 50.31) | 33.3 (9.92 to 65.11) | 27.3 (13.30 to 45.52) | 42.9 (26.32 to 60.65) | 35.3 (24.08 to 47.83) |
The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Clinical response per FMS is defined as a decrease in FMS ≥ 3 points and ≥ 30% from Baseline.
| percentage of participants | Main Study: M-PL | Main Study: M-SD | Main Study: M-HD | Main Study: M-SD + M-HD | Integrated Study (Main + Japan Sub-Study): M-PL | Integrated Study (Main + Japan Sub-Study): M-SD | Integrated Study (Main + Japan Sub-Study): M-HD | Integrated Study (Main + Japan Sub-Study): M-SD + M-HD |
|---|---|---|---|---|---|---|---|---|
| Ranked Secondary Endpoint 1: Percentage of Participants With Clinical Response Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period | 33.3 (9.92 to 65.11) | 61.3 (42.19 to 78.15) | 67.7 (48.63 to 83.32) | 64.5 (51.34 to 76.26) | 33.3 (9.92 to 65.11) | 57.6 (39.22 to 74.52) | 65.7 (47.79 to 80.87) | 61.8 (49.18 to 73.29) |
The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those participants with a decrease in PMS ≥ 2 points and ≥ 30% from Baseline. Mucosal healing per Mayo endoscopy subscore is defined as a subscore of ≤ 1.
| percentage of participants | Main Study: M-PL | Main Study: M-SD | Main Study: M-HD | Main Study: M-SD + M-HD | Integrated Study (Main + Japan Sub-Study): M-PL | Integrated Study (Main + Japan Sub-Study): M-SD | Integrated Study (Main + Japan Sub-Study): M-HD | Integrated Study (Main + Japan Sub-Study): M-SD + M-HD |
|---|---|---|---|---|---|---|---|---|
| Ranked Secondary Endpoint 2: Percentage of Participants With Mucosal Healing at Week 52 in Week 8 Responders Per PMS - Maintenance Period | 33.3 (9.92 to 65.11) | 38.7 (21.85 to 57.81) | 51.6 (33.06 to 69.85) | 45.2 (32.48 to 58.32) | 33.3 (9.92 to 65.11) | 36.4 (20.40 to 54.88) | 48.6 (31.38 to 66.01) | 42.6 (30.72 to 55.23) |
The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS remitters are defined as those participants with a PMS ≤ 2 and no individual subscore \> 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
| percentage of participants | Main Study: M-PL | Main Study: M-SD | Main Study: M-HD | Main Study: M-SD + M-HD | Integrated Study (Main + Japan Sub-Study): M-PL | Integrated Study (Main + Japan Sub-Study): M-SD | Integrated Study (Main + Japan Sub-Study): M-HD | Integrated Study (Main + Japan Sub-Study): M-SD + M-HD |
|---|---|---|---|---|---|---|---|---|
| Ranked Secondary Endpoint 3: Percentage of Participants With Clinical Remission Per FMS at Week 52 in Week 8 Remitters Per PMS - Maintenance Period | 37.5 (8.52 to 75.51) | 42.9 (21.82 to 65.98) | 45.5 (24.39 to 67.79) | 44.2 (29.08 to 60.12) | 37.5 (8.52 to 75.51) | 42.9 (21.82 to 65.98) | 44.0 (24.40 to 65.07) | 43.5 (28.93 to 58.89) |
The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). The PMS (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment). Negative changes indicate improvement. PMS responders are defined as those with a decrease in PMS ≥ 2 points and ≥ 30% from baseline. Among participants receiving systemic corticosteroids at Baseline, corticosteroid-free clinical remission per FMS at Week 52 is defined as having discontinued systemic corticosteroids prior to Week 52 and being in FMS clinical remission at Week 52 (defined as Mayo Score ≤ 2 and no individual subscore \> 1).
| percentage of participants | Main Study: M-PL | Main Study: M-SD | Main Study: M-HD | Main Study: M-SD + M-HD | Integrated Study (Main + Japan Sub-Study): M-PL | Integrated Study (Main + Japan Sub-Study): M-SD | Integrated Study (Main + Japan Sub-Study): M-HD | Integrated Study (Main + Japan Sub-Study): M-SD + M-HD |
|---|---|---|---|---|---|---|---|---|
| Ranked Secondary Endpoint 4: Percentage of Participants With Corticosteroid-Free Clinical Remission Per FMS at Week 52 in Week 8 Responders Per PMS - Maintenance Period | 40.0 (5.27 to 85.34) | 30.8 (9.09 to 61.43) | 31.3 (11.02 to 58.66) | 31.0 (15.28 to 50.83) | 40.0 (5.27 to 85.34) | 26.7 (7.79 to 55.10) | 35.3 (14.21 to 61.67) | 31.3 (16.12 to 50.01) |
Collected over See time frame specifics detailed for each reporting group in their respective descriptions below.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Integrated Study (Main + Japan Sub- Study): I-SD | 0/32 (0%) | 5/32 (15.6%) | 13/32 (40.6%) |
| Integrated Study (Main + Japan Sub- Study): I-HD | 0/51 (0%) | 4/51 (7.8%) | 16/51 (31.4%) |
| Integrated Study (Main + Japan Sub- Study): I-HD-OL | 0/18 (0%) | 1/18 (5.6%) | 14/18 (77.8%) |
| Integrated Study (Main + Japan Sub- Study): M-SD | 0/33 (0%) | 5/33 (15.2%) | 15/33 (45.5%) |
| Integrated Study (Main + Japan Sub- Study): M-HD | 0/36 (0%) | 5/36 (13.9%) | 20/36 (55.6%) |
| Integrated Study (Main + Japan Sub- Study): M-PL | 0/12 (0%) | 1/12 (8.3%) | 10/12 (83.3%) |
| Integrated Study (Main + Japan Sub- Study): Any Adalimumab | 0/101 (0%) | 22/101 (21.8%) | 65/101 (64.4%) |
| Event | Integrated Study (Main + Japan Sub- Study): I-SD | Integrated Study (Main + Japan Sub- Study): I-HD | Integrated Study (Main + Japan Sub- Study): I-HD-OL | Integrated Study (Main + Japan Sub- Study): M-SD | Integrated Study (Main + Japan Sub- Study): M-HD | Integrated Study (Main + Japan Sub- Study): M-PL | Integrated Study (Main + Japan Sub- Study): Any Adalimumab |
|---|---|---|---|---|---|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 2/32 | 2/51 | 1/18 | 3/33 | 0/36 | 0/12 | 10/101 |
| PSORIASISSkin and subcutaneous tissue disorders | 0/32 | 0/51 | 0/18 | 0/33 | 0/36 | 1/12 | 0/101 |
| ANAEMIABlood and lymphatic system disorders | 2/32 | 0/51 | 0/18 | 1/33 | 0/36 | 0/12 | 3/101 |
| GASTROENTERITISInfections and infestations | 0/32 | 0/51 | 0/18 | 2/33 | 0/36 | 0/12 | 2/101 |
| PERICARDITISCardiac disorders | 1/32 | 0/51 | 0/18 | 0/33 | 0/36 | 0/12 | 1/101 |
| HEADACHENervous system disorders | 1/32 | 0/51 | 0/18 | 0/33 | 0/36 | 0/12 | 1/101 |
| LOSS OF CONSCIOUSNESSNervous system disorders | 1/32 | 0/51 | 0/18 | 0/33 | 0/36 | 0/12 | 1/101 |
| ENTERITISGastrointestinal disorders | 0/32 | 0/51 | 0/18 | 1/33 | 0/36 | 0/12 | 1/101 |
| ENTERITIS INFECTIOUSInfections and infestations | 0/32 | 0/51 | 0/18 | 1/33 | 0/36 | 0/12 | 1/101 |
| DYSPEPSIAGastrointestinal disorders | 0/32 | 0/51 | 0/18 | 0/33 | 1/36 | 0/12 | 1/101 |
| Event | Integrated Study (Main + Japan Sub- Study): I-SD | Integrated Study (Main + Japan Sub- Study): I-HD | Integrated Study (Main + Japan Sub- Study): I-HD-OL | Integrated Study (Main + Japan Sub- Study): M-SD | Integrated Study (Main + Japan Sub- Study): M-HD | Integrated Study (Main + Japan Sub- Study): M-PL | Integrated Study (Main + Japan Sub- Study): Any Adalimumab |
|---|---|---|---|---|---|---|---|
| HEADACHENervous system disorders | 4/32 | 5/51 | 4/18 | 6/33 | 2/36 | 2/12 | 19/101 |
| COLITIS ULCERATIVEGastrointestinal disorders | 2/32 | 0/51 | 0/18 | 3/33 | 4/36 | 2/12 | 11/101 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/32 | 3/51 | 0/18 | 2/33 | 4/36 | 2/12 | 10/101 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 0/32 | 0/51 | 0/18 | 0/33 | 0/36 | 2/12 | 2/101 |
| NASOPHARYNGITISInfections and infestations | 2/32 | 2/51 | 1/18 | 3/33 | 4/36 | 1/12 | 12/101 |
| ABDOMINAL PAINGastrointestinal disorders | 0/32 | 2/51 | 2/18 | 1/33 | 1/36 | 1/12 | 6/101 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 1/32 | 1/51 | 2/18 | 2/33 | 1/36 | 0/12 | 7/101 |
| C-REACTIVE PROTEIN INCREASEDInvestigations | 0/32 | 1/51 | 0/18 | 3/33 | 0/36 | 0/12 | 5/101 |
| ANAEMIABlood and lymphatic system disorders | 1/32 | 3/51 | 1/18 | 2/33 | 1/36 | 1/12 | 9/101 |
| PHARYNGITISInfections and infestations | 2/32 | 1/51 | 1/18 | 2/33 | 1/36 | 1/12 | 9/101 |
| Age, Continuous(years) | Integrated Study (Main + Japan Sub- Study): I-SD | Integrated Study (Main + Japan Sub- Study): I-HD | Integrated Study (Main + Japan Sub- Study): I-HD-OL | Total |
|---|---|---|---|---|
| Mean | 14.7 ± 2.66 | 13.8 ± 3.06 | 13.8 ± 2.82 | 14.1 ± 2.90 |
| Sex: Female, Male(Participants) | Integrated Study (Main + Japan Sub- Study): I-SD | Integrated Study (Main + Japan Sub- Study): I-HD | Integrated Study (Main + Japan Sub- Study): I-HD-OL | Total |
|---|---|---|---|---|
| Female | 15 | 23 | 13 | 51 |
| Male | 17 | 28 | 5 | 50 |
| Race/Ethnicity, Customized(Participants) | Integrated Study (Main + Japan Sub- Study): I-SD | Integrated Study (Main + Japan Sub- Study): I-HD | Integrated Study (Main + Japan Sub- Study): I-HD-OL | Total |
|---|---|---|---|---|
| White | 28 | 45 | 15 | 88 |
| Black | 1 | 2 | 0 | 3 |
| Asian | 3 | 4 | 2 | 9 |
| Multiple | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Integrated Study (Main + Japan Sub- Study): I-SD | Integrated Study (Main + Japan Sub- Study): I-HD | Integrated Study (Main + Japan Sub- Study): I-HD-OL | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 1 | 4 |
| Japanese | 2 | 4 | 2 | 8 |
| No Ethnicity | 29 | 45 | 15 | 89 |
| Full Mayo Score (FMS)(score on a scale) | Integrated Study (Main + Japan Sub- Study): I-SD | Integrated Study (Main + Japan Sub- Study): I-HD | Integrated Study (Main + Japan Sub- Study): I-HD-OL | Total |
|---|---|---|---|---|
| Mean | 7.8 ± 1.22 | 7.7 ± 1.25 | 7.7 ± 1.09 | 7.8 ± 1.20 |
| Partial Mayo Score (PMS)(score on a scale) | Integrated Study (Main + Japan Sub- Study): I-SD | Integrated Study (Main + Japan Sub- Study): I-HD | Integrated Study (Main + Japan Sub- Study): I-HD-OL | Total |
|---|---|---|---|---|
| Mean | 5.7 ± 1.14 | 5.5 ± 1.24 | 5.5 ± 1.06 | 5.6 ± 1.17 |
| Endoscopy Subscore(score on a scale) | Integrated Study (Main + Japan Sub- Study): I-SD | Integrated Study (Main + Japan Sub- Study): I-HD | Integrated Study (Main + Japan Sub- Study): I-HD-OL | Total |
|---|---|---|---|---|
| Mean | 2.1 ± 0.34 | 2.2 ± 0.40 | 2.2 ± 0.43 | 2.2 ± 0.38 |
| Rectal Bleeding Subscore(score on a scale) | Integrated Study (Main + Japan Sub- Study): I-SD | Integrated Study (Main + Japan Sub- Study): I-HD | Integrated Study (Main + Japan Sub- Study): I-HD-OL | Total |
|---|---|---|---|---|
| Mean | 1.4 ± 0.93 | 1.5 ± 0.88 | 1.4 ± 0.97 | 1.5 ± 0.91 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Oct 2014 to primary completion in Feb 2020, 63 months.
Results were first posted in Oct 2020, 7 months after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 63 months is above that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab